Sheetal H Shah

发表

Pomalidomide In Sickle Cell Disease: Phase I Study Of a Novel Anti-Switching Agent

P. Swerdlow, A. Kutlar, R. Knight, 2013 .

A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

C. Hofmeister, S. Lonial, J. Laubach, 2015 .

Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.

E. Kimby, J. Gribben, F. Bosch, 2008 .

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

E. Kimby, J. Gribben, F. Bosch, 2010 .

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia

E. Kimby, J. Gribben, F. Bosch, 2012, Leukemia & lymphoma.

Effect of chronic glucocorticoid therapy and the gender difference on bone mineral density in liver transplant patients.

H. Jeon, T. Johnston, D. Ranjan, 2006, The Journal of surgical research.

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

C. Hofmeister, S. Lonial, J. Laubach, 2013 .

Predicting dry weight in patients with ascites and liver cirrhosis using computed tomography imaging.

P. McHugh, R. Gedaly, T. Johnston, 2010, Hepato-gastroenterology.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

P. Fenaux, A. Raza, M. Sekeres, 2022, Blood.

MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).

C. Hofmeister, S. Lonial, D. Siegel, 2013 .

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

M. Sekeres, U. Platzbecker, V. Santini, 2023, The Lancet.

MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.

C. Hofmeister, S. Lonial, D. Siegel, 2014 .

A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).

P. Sonneveld, C. Hofmeister, D. Siegel, 2016 .